Latest Information Update: 11 Jul 2007
At a glance
- Originator Sepracor
- Mechanism of Action Adrenergic receptor antagonists; Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 18 Apr 2001 New profile
- 18 Apr 2001 Preclinical development for CNS disorders in USA (Unknown route)